New Chinese drug extends stroke treatment window from hours to 2 days: study finds
A new clinical trial has identified a neuroprotective drug called loberamisal that extends the effective treatment window for ischemic strokes from six hours to 48 hours. The study, published in JAMA, showed that patients receiving the drug achieved significantly higher functional recovery rates.
Why it matters
Expanding the treatment window for strokes could drastically reduce permanent disability and mortality rates globally by allowing more patients to receive life-saving interventions.
Home News World Sports Entertainment Science Royal Trending Health Videos Technology New Chinese drug extends stroke treatment window from hours to 2 days: study finds A new clinical trial shows neuroprotective drug loberamisal significantly improves stroke recovery when given within 48 hours
As strokes are one of the most common health issue among adults, Chinese scientists have developed a novel neuroprotective drug that successfully extends the critical stroke treatment window from hours to two days.
Strokes happen when brain cells start dying within minutes of a clot blocking an artery, leading to facial drooping, affected speech, and, in severe cases, paralysis or death.
Traditionally, emergency interventions for acute ischemic strokes such as clot-busting drugs (like alteplase) or surgical mechanical thrombectomies face a notoriously rigid, narrow time window typically ranging from 3 to 6 hours to prevent permanent brain damage or death.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in